Oral Bacterial Lysate OM-85 Prevents Respiratory Tract Infections in Asthma: The OMRIA RWE Study.

IF 3.7 3区医学 Q2 ALLERGY

Journal of Asthma and Allergy Pub Date : 2025-06-02 eCollection Date: 2025-01-01 DOI:10.2147/JAA.S517194

Maria Elpida Christopoulou, Lilia S Panteli, John A Moisidis, Ioannis A Christopoulos, Maria Eleni Kasimeri, Amalia S Tryphonidou, Antonios I Christopoulos

{"title":"Oral Bacterial Lysate OM-85 Prevents Respiratory Tract Infections in Asthma: The OMRIA RWE Study.","authors":"Maria Elpida Christopoulou, Lilia S Panteli, John A Moisidis, Ioannis A Christopoulos, Maria Eleni Kasimeri, Amalia S Tryphonidou, Antonios I Christopoulos","doi":"10.2147/JAA.S517194","DOIUrl":null,"url":null,"abstract":"Background: OM-85 is a well-characterized bacterial lysate with antiviral properties, enhancement of airway epithelial barrier function, and tolerance induction. However, real-world evidence is needed to evaluate its effectiveness as an add-on therapy in patients with allergic asthma.Methods: This retrospective cohort study analyzed medical records of 137 adults with moderate to severe allergic asthma over 12 months. Patients receiving standard of care (SoC) asthma therapy alone (GINA step 4, n = 67) were compared to those on SoC+OM-85 (n = 70). All symptom episodes (CEPs) indicative of respiratory tract infections (RTIs) were recorded, and a 3-scale mean severity index (mSI) was calculated. Propensity score weighting was used for Poisson and linear regression analyses.Results: Patients on OM-85 demonstrated significant reductions in the number of CEPs (60%), asthma exacerbations (71%), unscheduled visits (72%), oral corticosteroid courses (73%), and antibiotic cycles (67%). The mSI was 1.15 points lower in the OM-85 group (p < 0.001).Conclusion: OM-85 as an add-on to standard asthma therapy significantly reduced RTI-related episodes, exacerbations, and healthcare utilization while lowering symptom severity in adults with allergic asthma.","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"891-902"},"PeriodicalIF":3.7000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143292/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma and Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JAA.S517194","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: OM-85 is a well-characterized bacterial lysate with antiviral properties, enhancement of airway epithelial barrier function, and tolerance induction. However, real-world evidence is needed to evaluate its effectiveness as an add-on therapy in patients with allergic asthma.

Methods: This retrospective cohort study analyzed medical records of 137 adults with moderate to severe allergic asthma over 12 months. Patients receiving standard of care (SoC) asthma therapy alone (GINA step 4, n = 67) were compared to those on SoC+OM-85 (n = 70). All symptom episodes (CEPs) indicative of respiratory tract infections (RTIs) were recorded, and a 3-scale mean severity index (mSI) was calculated. Propensity score weighting was used for Poisson and linear regression analyses.

Results: Patients on OM-85 demonstrated significant reductions in the number of CEPs (60%), asthma exacerbations (71%), unscheduled visits (72%), oral corticosteroid courses (73%), and antibiotic cycles (67%). The mSI was 1.15 points lower in the OM-85 group (p < 0.001).

Conclusion: OM-85 as an add-on to standard asthma therapy significantly reduced RTI-related episodes, exacerbations, and healthcare utilization while lowering symptom severity in adults with allergic asthma.

查看原文本刊更多论文

口服细菌裂解液OM-85预防哮喘呼吸道感染：OMRIA RWE研究

背景：OM-85是一种特性良好的细菌裂解物，具有抗病毒特性，增强气道上皮屏障功能，并诱导耐受性。然而，需要真实的证据来评估其作为过敏性哮喘患者附加治疗的有效性。方法：本回顾性队列研究分析了137例成人中重度过敏性哮喘患者12个月以上的医疗记录。将单独接受标准护理（SoC）哮喘治疗（GINA步骤4，n = 67）的患者与接受SoC+OM-85治疗的患者（n = 70）进行比较。记录所有指示呼吸道感染（RTIs）的症状发作（cep），并计算3量表平均严重程度指数（mSI）。倾向得分加权用于泊松和线性回归分析。结果：服用OM-85的患者在cep次数（60%）、哮喘加重（71%）、计划外就诊（72%）、口服皮质类固醇疗程（73%）和抗生素周期（67%）方面均有显著减少。OM-85组的mSI低1.15点（p < 0.001）。结论：OM-85作为标准哮喘治疗的附加治疗可显著减少rti相关发作、加重和医疗保健利用，同时降低成人过敏性哮喘的症状严重程度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Asthma and Allergy Medicine-Immunology and Allergy

CiteScore

5.30

自引率

6.20%

发文量

185

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. Although the main focus of the journal will be to publish research and clinical results in humans, preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies.